Cargando…
Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
BACKGROUND: The mechanism of resistance development to anti-VEGF therapy in ovarian cancer is unclear. We focused on the changes in tumour immunity post anti-VEGF therapy. METHODS: The frequencies of immune cell populations and hypoxic conditions in the resistant murine tumours and clinical samples...
Autores principales: | Horikawa, Naoki, Abiko, Kaoru, Matsumura, Noriomi, Baba, Tsukasa, Hamanishi, Junzo, Yamaguchi, Ken, Murakami, Ryusuke, Taki, Mana, Ukita, Masayo, Hosoe, Yuko, Koshiyama, Masafumi, Konishi, Ikuo, Mandai, Masaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078258/ https://www.ncbi.nlm.nih.gov/pubmed/31932754 http://dx.doi.org/10.1038/s41416-019-0725-x |
Ejemplares similares
-
Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
por: Horikawa, Naoki, et al.
Publicado: (2015) -
Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation
por: Taki, Mana, et al.
Publicado: (2018) -
Acquisition of a side population fraction augments malignant phenotype in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2019) -
Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Murakami, Ryusuke, et al.
Publicado: (2021) -
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)